Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Elevated Serum IL-17A but not IL-6 in Glioma Versus Meningioma and Schwannoma

  • Doroudchi, Mehrnoosh (Department of Immunology, School of Medicine, Shiraz University of Medical Sciences) ;
  • Pishe, Zahra Ghanaat (Shiraz University of Medical Sciences) ;
  • Malekzadeh, Mahyar (Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences) ;
  • Golmoghaddam, Hossein (Department of Immunology, School of Medicine, Shiraz University of Medical Sciences) ;
  • Taghipour, Mousa (Shiraz University of Medical Sciences) ;
  • Ghaderi, Abbas (Department of Immunology, School of Medicine, Shiraz University of Medical Sciences)
  • Published : 2013.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background: There is a Th1/Th2 cytokine imbalance and expression of IL-17 in patients with brain tumours. We aimed to compare the levels of IL-17A and IL-6 in sera of glioma, meningioma and schwannoma patients as well as in healthy individuals. Materials and Methods: IL-17A and IL-6 levels were measured in sera of 38 glioma, 24 meningioma and 18 schwannoma patients for comparison with 26 healthy controls by commercial ELISA assays. Results: We observed an increase in the IL-17A in 30% of glioma patients while only 4% and 5.5% of meningioma and schwannoma patients and none of the healthy controls showed elevated IL-17A in their sera ($0.29{\pm}0.54$, $0.03{\pm}0.15$ and $0.16{\pm}0.68$ vs. $0.00{\pm}0.00pg/ml$; p=0.01, p=0.01 and p=0.001, respectively). There was also a significant decrease in the level of IL-6 in glioma patients compared to healthy controls ($2.34{\pm}4.35$ vs. $4.67{\pm}4.32pg/ml$; p=0.01). There was a direct correlation between the level of IL-17A and age in glioma patients (p=0.005). Glioma patients over 30 years of age had higher IL-17A and lower IL-6 in their sera compared to the young patients. In addition, a non-significant grade-specific inverse trend between IL-17A and IL-6 was observed in glioma patients, where high-grade gliomas had higher IL-17A and lower IL-6. Conclusions: Our data suggest a Th17 mediated inflammatory response in the pathogenesis of glioma. Moreover, tuning of IL-6 and IL-17A inflammatory cytokines occurs during progression of glioma. IL-17A may be a potential biomarker and/or immunotherapeutic target in glioma cases.

Keywords

References

  1. Alvarez-Rodriguez L, Lopez-Hoyos M, Munoz-Cacho P, Martinez-Taboada VM (2012). Aging is associated with circulating cytokine dysregulation. Cell Immunol, 273, 124-32. https://doi.org/10.1016/j.cellimm.2012.01.001
  2. Arima T, Natsume A, Hatano H, et al (2005). Intraventricular chordoid meningioma presenting with Castleman disease due to overproduction of interleukin-6. Case report. J Neurosurg, 102, 733-7. https://doi.org/10.3171/jns.2005.102.4.0733
  3. Benchetrit F, Ciree A, Vives V, et al (2002). Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood, 99, 2114-21. https://doi.org/10.1182/blood.V99.6.2114
  4. Bondy ML, Scheurer ME, Malmer B, et al (2008). Brain tumor epidemiology consortium. brain tumor epidemiology: consensus from the brain tumor epidemiology consortium. Cancer, 113, 1953-68. https://doi.org/10.1002/cncr.23741
  5. Damasceno M (2011). Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer. Curr Opin Oncol, 23, 3-9. https://doi.org/10.1097/01.cco.0000397417.75245.9c
  6. Doroudchi M, Saidi M, Malekzadeh M, et al (2013). Elevated IL-17A levels in early stages of bladder cancer regardless of smoking status. Future Oncol, 992, 295-304.
  7. Fong B, Barkhoudarian G, Pezeshkian P, et al (2011). The molecular biology and novel treatments of vestibular schwannomas. J Neurosurg, 115, 906-14. https://doi.org/10.3171/2011.6.JNS11131
  8. Gridley DS, Loredo LN, Slater JD, et al (1998). Pilot evaluation of cytokine levels in patients undergoing radiotherapy for brain tumor. Cancer Detect Prev, 22, 20-9. https://doi.org/10.1046/j.1525-1500.1998.00010.x
  9. Gutierrez C, Schiff R (2011). HER2: biology, detection, and clinical implications. Arch Pathol Lab Med, 135, 55-62.
  10. Hu J, Mao Y, Li M, Lu Y (2011). The profile of Th17 subset in glioma. Int Immunopharmacol, 11, 1173-9. https://doi.org/10.1016/j.intimp.2011.03.015
  11. Jarnicki A, Putoczki T, Ernst M (2010). Stat3: linking inflammation to epithelial cancer- more than a "gut" feeling? Cell Div, 5, 14. https://doi.org/10.1186/1747-1028-5-14
  12. Jiang Y, Uhrbom L (2012). On the origin of glioma. Ups J Med Sci, 117, 113-21. https://doi.org/10.3109/03009734.2012.658976
  13. Kantelhardt SR, Caarls W, de Vries AH, et al (2010). Specific visualization of glioma cells in living low-grade tumor tissue. PLoS One, 5, 11323. https://doi.org/10.1371/journal.pone.0011323
  14. Kryczek I, Wei S, Zou L, et al (2007). Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol, 178, 6730-3. https://doi.org/10.4049/jimmunol.178.11.6730
  15. Kujas M (1993). Meningioma. Curr Opin Neurol, 6, 882-7. https://doi.org/10.1097/00019052-199312000-00009
  16. Kumar R, Kamdar D, Madden L, et al (2006). Th1/Th2 cytokine imbalance in meningioma, anaplastic astrocytoma and glioblastoma multiforme patients. Oncol Rep, 15, 1513-6.
  17. Lee HK, Seo IA, Suh DJ, et al (2009). Interleukin-6 is required for the early induction of glial fibrillary acidic protein in Schwann cells during Wallerian degeneration. J Neurochem, 108, 776-86. https://doi.org/10.1111/j.1471-4159.2008.05826.x
  18. Louis DN, Ohgaki H, Wiestler OD, et al (2007). The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol, 114, 97-109. https://doi.org/10.1007/s00401-007-0243-4
  19. MacKenzie DJ (1926). A classification of the tumours of the glioma group on a histogenetic basis with a correlated study of prognosis. Can Med Assoc J, 16, 872.
  20. Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancerrelated inflammation. Nature, 454, 436-44. https://doi.org/10.1038/nature07205
  21. Martin-Orozco N, Muranski P, Chung Y, et al (2009). T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity, 31, 787-98. https://doi.org/10.1016/j.immuni.2009.09.014
  22. Martin-Villalba A, Okuducu AF, von Deimling A (2008). The evolution of our understanding on glioma. Brain Pathol, 18, 455-63. https://doi.org/10.1111/j.1750-3639.2008.00136.x
  23. Merlo A, Juretic A, Zuber M, et al (1993). Cytokine gene expression in primary brain tumours, metastases and meningiomas suggests specific transcription patterns. Eur J Cancer, 29, 2118-25. https://doi.org/10.1016/0959-8049(93)90046-I
  24. Michaud DS, Gallo V, Schlehofer B, et al (2010). Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study. Cancer Epidemiol Biomarkers Prev, 19, 2562-9. https://doi.org/10.1158/1055-9965.EPI-10-0447
  25. Minniti G, Amichetti M, Enrici RM (2009). Radiotherapy and radiosurgery for benign skull base meningiomas. Radiat Oncol, 4, 42. https://doi.org/10.1186/1748-717X-4-42
  26. Miyahara Y, Odunsi K, Chen W, et al (2008). Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci USA, 105, 15505-10. https://doi.org/10.1073/pnas.0710686105
  27. Norden DA, Reardon AD, Wen YCP (2010). Primary central nervous system tumors: pathogenesis and therapy (Current Clinical Oncology). New York: Hummana: 2011 edition.
  28. Numasaki M, Fukushi J, Ono M, et al (2003). Interleukin-17 promotes angiogenesis and tumor growth. Blood, 101, 2620-7. https://doi.org/10.1182/blood-2002-05-1461
  29. Park KJ, Kang SH, Chae YS, et al (2010). Influence of interleukin-6 on the development of peritumoral brain edema in meningiomas. J Neurosurg, 112, 73-80. https://doi.org/10.3171/2009.4.JNS09158
  30. Pfisterer WK, Hank NC, Preul MC, et al (2004). Diagnostic and prognostic significance of genetic regional heterogeneity in meningiomas. Neuro Oncol, 6, 290-9. https://doi.org/10.1215/S1152851704000158
  31. Pouratian N, Schiff D (2010). Management of low-grade glioma. Curr Neurol Neurosci Rep, 10, 224-31. https://doi.org/10.1007/s11910-010-0105-7
  32. Rahaman SO, Harbor PC, Chernova O, et al (2002). Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene, 21, 8404-13. https://doi.org/10.1038/sj.onc.1206047
  33. Reihmane D, Jurka A, Tretjakovs P, Dela F (2013). Increase in IL-6, TNF-$\alpha$, and MMP-9, but not sICAM-1 concentrations depends on exercise duration. Eur J Appl Physiol, 113, 851-8. https://doi.org/10.1007/s00421-012-2491-9
  34. Riemenschneider MJ, Jeuken JW, Wesseling P, Reifenberger G (2010). Molecular diagnostics of gliomas: state of the art. Acta Neuropathol, 120, 567-84. https://doi.org/10.1007/s00401-010-0736-4
  35. Rittierodt M, Tschernig T, Samii M, et al (2001). Evidence of recurrent atypical meningioma with rhabdoid transformation and expression of pyrogenic cytokines in a child presenting with a marked acute-phase response: case report and review of the literature. J Neuroimmunol, 120, 129-37. https://doi.org/10.1016/S0165-5728(01)00425-8
  36. Sato T, Sugiyama T, Kawataki T, et al (2010). Clear cell meningioma causing Castleman syndrome in a child. J Neurosurg Pediatr, 5, 622-5. https://doi.org/10.3171/2010.1.PEDS09413
  37. Sfanos KS, Bruno TC, Maris CH, et al (2008). Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing. Clin Cancer Res, 14, 3254-61. https://doi.org/10.1158/1078-0432.CCR-07-5164
  38. Sherry MM, Reeves A, Wu JK, Cochran BH (2009). STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells, 27, 2383-92. https://doi.org/10.1002/stem.185
  39. Sim M, Dawson B, Landers G, et al (2013). Effect of exercise modality and intensity on post-exercise interleukin-6 and hepcidin levels. Int J Sport Nutr Exerc Metab, 23, 178-86. https://doi.org/10.1123/ijsnem.23.2.178
  40. Sreekanthreddy P, Srinivasan H, Kumar DM, et al (2010). Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis. Cancer Epidemiol Biomarkers Prev, 19, 1409-22. https://doi.org/10.1158/1055-9965.EPI-09-1077
  41. Tofaris GK, Patterson PH, Jessen KR, Mirsky R (2002). Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. J Neurosci, 22, 6696-703.
  42. Van Meir E, Sawamura Y, Diserens AC, et al (1990). Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res, 50, 6683-8.
  43. Wang L, Yi T, Kortylewski M, et al (2009). IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med, 206, 1457-64. https://doi.org/10.1084/jem.20090207
  44. Wernicke AG, Dicker AP, Whiton M, et al (2010). Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. Radiat Oncol, 5, 46. https://doi.org/10.1186/1748-717X-5-46
  45. Wiemels J, Wrensch M, Claus EB (2010). Epidemiology and etiology of meningioma. J Neurooncol, 99, 307-14. https://doi.org/10.1007/s11060-010-0386-3
  46. Zhang B, Rong G, Wei H, et al (2008). The prevalence of Th17 cells in patients with gastric cancer. Biochem Biophys Res Commun, 374, 533-7. https://doi.org/10.1016/j.bbrc.2008.07.060
  47. Zhang Y, Yu J, Qu L, Li Y (2012). Calcification of vestibular schwannoma: a case report and literature review. World J Surg Oncol, 10, 207. https://doi.org/10.1186/1477-7819-10-207
  48. Zhou J, Tryggestad E, Wen Z, et al (2011). Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nat Med, 17, 130-4. https://doi.org/10.1038/nm.2268

Cited by

  1. Expression of Neuronal Markers, NFP and GFAP, in Malignant Astrocytoma vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6315
  2. Comparison of Linear Accelerator and Helical Tomotherapy Plans for Glioblastoma Multiforme Patients vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7811
  3. Application of Computed Tomography for Differential Diagnosis of Glioma Stoke and Simple Cerebral Hemorrhage vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3425
  4. Th17 Cells in Autoimmune and Infectious Diseases vol.2014, pp.2042-0099, 2014, https://doi.org/10.1155/2014/651503
  5. IL-17A Levels in the Sera of Patients with Gastric Cancer Show Limited Elevation vol.16, pp.16, 2015, https://doi.org/10.7314/APJCP.2015.16.16.7149
  6. The evaluation of the serum level of IL-10 in OLP patients pp.1618-565X, 2017, https://doi.org/10.1007/s00580-017-2564-6
  7. Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type vol.17, pp.9, 2016, https://doi.org/10.3390/ijms17091433
  8. Prognostic role of high sensitivity C-reactive protein and interleukin-6 in glioma and meningioma patients vol.138, pp.2, 2018, https://doi.org/10.1007/s11060-018-2803-y